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C. Keith Ozaki, MD, Chicago, Ill
With the overall goal of enhancing the effectiveness and efﬁciency of vascular care, the Society for Vascular Surgery (SVS)
recently completed a process by which it identiﬁed its top clinical research priorities to address critical gaps in knowledge
guiding practitioners in prevention and treatment of vascular disease. After a survey of the SVS membership, a panel of
SVS committee members and opinion leaders considered 53 distinct research questions through a structured process that
resulted in identiﬁcation of nine clinical issues that were felt to merit immediate attention by vascular investigators and
external funding agencies. These are, in order of priority: (1) deﬁne optimal management of asymptomatic carotid
stenosis, (2) compare the effectiveness of medical vs invasive treatment (open or endovascular) of vasculogenic claudi-
cation, (3) compare effectiveness of open vs endovascular infrainguinal revascularization as initial treatment of critical
limb ischemia, (4) develop and compare the effectiveness of clinical strategies to reduce cardiovascular and other peri-
operative complications (eg, wound) after vascular intervention, (5) compare the effectiveness of strategies to enhance
arteriovenous ﬁstula maturation and durability, (6) develop best practices for management of chronic venous ulcer,
(7) deﬁne optimal adjunctive medical therapy to enhance the success of lower extremity revascularization, (8) identify and
evaluate medical therapy to prevent abdominal aortic aneurysm growth, and (9) evaluate ultrasound vs computed
tomographic angiography surveillance after endovascular aneurysm repair. (J Vasc Surg 2013;57:493-500.)In the fall of 2010, the Society for Vascular Surgery
(SVS) Research Council proposed to the SVS Board of
Directors that the Society intensify its emphasis on clinical
research through several initiatives that have now been
adopted and implemented: (1) establish a process by which
investigator-initiated clinical research projects could be
formally reviewed by the SVS and receive a statement of
approval that might improve the chances of receiving extra-
mural research funding, accelerate subject recruitment,
and study completion1; (2) create a funding mechanism to
facilitate development, preparation, and submission of
investigator-initiated multicenter clinical trial proposals—
a planning grant2; and (3) delineate clinical research priori-
ties for the SVS to guide research strategy and investment
over the next 5 years. This proposal included an electronic
survey of all SVS members then convening a stakeholder’s
conference where a broad cross-section of SVS leadership
determined the ﬁnal prioritization.the Research Council, Society for Vascular Surgery.
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The notion that the SVS should set for itself clinical
research priorities and also make recommendations to the
broader vascular community regarding these priorities
was stimulated by the release of the report “Initial National
Priorities for Comparative Effectiveness Research” by the
Institute of Medicine (IOM).3
For the purposes of this activity, the IOM’s deﬁnition
of comparative effectiveness research (CER) was adopted:
“Comparative effectiveness research (CER) is the gener-
ation and synthesis of evidence that compares the beneﬁts
and harms of alternative methods to prevent, diagnose,
treat, and monitor a clinical condition or to improve the
delivery of care. The purpose of CER is to assist consumers,
clinicians, purchasers, and policy makers to make informed
decisions that will improve health care at both the individual
and populations levels.”3
While CER encompasses population health care, the
SVS emphasizes that the surgeon’s primary obligation is
to the individual patient. Although CER has clearly assumed
national importance, the SVS also recognizes that there is
still important clinical research to be done in many areas
of vascular disease that do not necessarily meet the strict
deﬁnition of CER. Thus, during this activity, non-CER clin-
ical research priorities were included.
METHODS
SVS member survey on clinical research needs.
From the beginning, the Research Council sought to make493
Table I. SVS clinical research priorities stakeholders’
meeting
Participants
B. Timothy Baxter
Richard Cambria
Alexander Clowes
Elliot Chaikof Speaker, aortic disease
Mark Conrad
Michael Conte
Jack Cronenwett
R. Clement Darling
Mark Davies
Randolph Geary
Patrick Geraghty
David Gillespie
Peter Gloviczki
Kimberley Hansen Speaker, renal/mesenteric disease
Peter Henke Speaker, medical management/risk factors
Thomas Huber Speaker, dialysis access
Melina Kibbe
Larry Kraiss
Greg Landry
Mark Meissner Speaker, venous disease
Joseph Mills
Greg Moneta
Nicholas Morrissey
Peter Nelson
Louis Nguyen Speaker, economic considerations
Christopher Owens
C. Keith Ozaki
Richard Powell
Amy Reed
John Ricotta Speaker, carotid disease
Caron Rockman
Russell Samson
Andres Schanzer
Marc Schermerhorn
Michael Stoner Speaker, peripheral arterial disease
Ravi Veeraswamy
Omaida Velazquez
Rodney White
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vascular disease a “grass roots” activity. To that end, two
distinct surveying efforts were carried out. The ﬁrst (spring
of 2011) was patterned after that used by the IOM to
solicit feedback regarding the national CER priorities.3
Later (summer of 2011), an abridged version of the
survey instrument was distributed again to the entire SVS
membership merely asking them to state in the form of
a question clinical issues where better evidence was needed
to guide patient care.
Then, survey results were reviewed by the Research
Council, which eliminated duplicates and grouped similar
responses into more generally framed questions and then
categorized them into the following themes: (1) carotid
disease, (2) aortic disease, (3) mesenteric and renal artery
disease, (4) peripheral arterial disease, (5) dialysis access,
(6) venous disease, and (7) medical management of vas-
cular disease and risk factor modiﬁcation.
The Research Council, in consultation with the Execu-
tive Committee, then organized a stakeholder’s meeting
to review results of the membership survey. The SVS
members recognized as opinion leaders in the seven cate-
gories listed above were recruited to review the submitted
survey responses for completeness, making sure that the
major outstanding questions in each theme were repre-
sented in the set of responses from the membership survey.
Chairs of SVS committees whose missions were relevant to
clinical research were also asked to select one or two repre-
sentatives from their committee to attend this meeting.
Stakeholders’ meeting. The SVS Clinical Research
Priorities Meeting was convened in Chicago, Illinois, on
October 14-15, 2011.Attendees comprised 38SVSmembers
who were serving in Society leadership positions or had
established reputations in vascular research (Table I).
During the ﬁrst half-day of the meeting, the partici-
pants were provided an overview of the economic consider-
ations in clinical vascular research, followed by focused
presentations by thought leaders in each of the seven iden-
tiﬁed content areas (see Table I for speakers). Each speaker
was tasked to address the following elements relative to
their assigned content area: What is the incidence/preva-
lence of disease in that area? What is the cost of caring
for disease in that area? How good is the current evidence
that guides decision making in that area? What major
unanswered questions exist in that area? What trials are
currently underway addressing unanswered questions in
that area?
During the second half-day of the meeting, participants
were divided into six groups with six to seven members,
and each group reviewed and scored at least two-thirds
of the research topics submitted for prioritization using
a standard tool (Fig). The process ensured that each
research question was scored by at least four groups. Scores
were tallied, and questions receiving the highest scores
were submitted for ﬁnal prioritization during the next
session.
The last half-day of the meeting consisted of a plenary
session where a variation of the Improved Nominal GroupTechnique of decision making was used.4 This decision-
making process is designed to allow each member of
a group the opportunity to voice his or her opinion, but
it also empowers less vocal members of the group to inﬂu-
ence the ﬁnal decision through proportional voting.
A list of the top scoring questions as determined by the
small groups was distributed to all meeting attendees. In
plenary session, each question was individually reviewed,
and opinions for or against high prioritization were soli-
cited. After this discussion period, each participant was
given 20 “virtual” dollars to “spend” on the research topics
they felt should receive highest emphasis by the SVS.
Participants were free to spend all their money on a single,
high-priority topic, or they could spread their spending on
as many topics as they felt appropriate. The ﬁnal results of
the voting (as tallied by the amount of virtual money the
participants invested in each topic) were again presented
in a plenary session before adjournment in order to conﬁrm
consensus regarding the ﬁnal ranking.
Fig. Small group question evaluation tool.
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ing, a questionnaire was circulated to the attendees asking
them for their thoughts regarding the validity and value of
the entire process.RESULTS
SVS member survey results. The two SVS member
surveys generated 192 distinct responses. After review of
the raw data by the Research Council and the selected
thought leaders, a ﬁnal set of 53 topics in seven content
areas (Table II) was developed for consideration at the
stakeholders’ meeting.Stakeholders’ meeting presentations. The content of
the speaker presentations can be viewed at http://www.
vascularweb.org/research/clinicalresearch/Pages/Clinical-
Research-Priorities-.aspx.
Small group scoring outcome. The results of the
small group exercise are presented in Table III. A more
complete report of the small group exercise, including
component scores as well as the number of reviewers
who scored each question, is available at http://www.
vascularweb.org/research/clinicalresearch/Pages/Clinical-
Research-Priorities-.aspx.
The Research Council met after the small group exer-
cise to review the scores and selected the 19 top scoring
Table II. Questions for small group review
Carotid artery disease (31 original questions)
C1. Compare effectiveness of CEA vs CAS for asymptomatic stenosis
C2. Compare effectiveness of CEA vs CAS for symptomatic stenosis
C3. Compare effectiveness of invasive intervention (CEA or CAS) with medical therapy for asymptomatic carotid
stenosis
C4. Compare effectiveness of invasive intervention (CEA or CAS) with medical therapy for symptomatic carotid stenosis
C5. Deﬁne clinical and anatomic characteristics in asymptomatic carotid stenosis patients that place them at high risk
for stroke
C6. Deﬁne cost-effective algorithms for imaging carotid disease
C7. Compare observational vs interventional treatment for postintervention carotid restenosis
C8. Deﬁne the role of simultaneous carotid-CABG revascularization
C9. Deﬁne the optimal management of patients with low-frequency carotid artery-related pathologies
(eg, hyperperfusion syndrome, dissections, FMD)
Aortic disease (29 original questions)
A1. Compare effectiveness of open vs endovascular repair of ascending and arch aortic aneurysms
A2. Compare effectiveness of open vs endovascular repair of thoracoabdominal aneurysms (assume stratiﬁcation
by extent)
A3. Evaluate US vs CTA surveillance post-EVAR
A4. Compare treatment vs observation in AAAs measuring 5.5-6.0 cm in diameter
A5. Determine the natural history of AAAs measuring 5.0-5.5 cm in diameter
A6. Compare effectiveness of open vs endovascular repair of acute type B aortic dissections
A7. Compare effectiveness of open vs endovascular repair of chronic type B aortic dissections
A8. Identify and evaluate medical therapy to prevent AAA growth
A9. Establish guidelines for screening and deﬁne the “high-risk” small AAAs (<5.5 cm)
Mesenteric/renal disease (10 original questions)
R1. Compare effectiveness of medical therapy vs stenting of severe renal artery disease stratiﬁed by presence of
hypertension and renal insufﬁciency
R2. Compare effectiveness of open vs endovascular mesenteric revascularization
Peripheral arterial disease (72 original questions)
P1. Compare effectiveness of initial open vs endovascular infrainguinal revascularization for CLI
P2. Compare effectiveness of staged vs simultaneous amputation in patients undergoing lower extremity
revascularization with toe or forefoot gangrene
P3. Deﬁne and evaluate novel strategies for management of unreconstructible CLI including cell- and gene-based
therapy
P4. Deﬁne the role of primary amputation in CLI
P5. Identify the factors predicting successful prosthetic rehabilitation after lower extremity amputation
P6. Develop algorithms for cost-effective use of lower extremity revascularization in CLI
P7. Compare effectiveness of medical vs invasive therapy (open or endovascular) for claudication
P8. Deﬁne the role of infrapopliteal revascularization in diabetics before clinical CLI develops
P9. Compare effectiveness of initial open vs endovascular infrainguinal revascularization for claudication
P10. Develop algorithms for cost-effective use of lower extremity revascularization in claudication
P11. Compare duplex vs arteriography as completion study after surgical lower extremity bypass
P12. Deﬁne best medical antiplatelet therapy after intervention for PAD
P13. Evaluate effectiveness of duplex scanning as a surveillance tool to identify and treat asymptomatic recurrence
after endovascular intervention
P14. Evaluate methods of diagnosing and treating lower extremity entrapment syndromes
P15. Compare open vs endovascular management of popliteal aneurysms
P16. Develop validated quality-of-life measures for patients with vascular disease
Dialysis (16 original questions)
D1. Develop a comprehensive cost-effective algorithm for hemodialysis access
D2. Deﬁne the optimal form of dialysis access for patients with unsuitable or failed forearm ﬁstulas
D3. Compare the effectiveness of secondary interventions to preserve existing dialysis access ﬁstulas and grafts
D4. Deﬁne the optimal approach for dialysis access in-patient with central venous stenosis
D5. Determine the effectiveness of strategies to enhance AV ﬁstula maturation
D6. Compare the overall effectiveness of single-stage vs two-stage basilic vein transposition for hemodialysis access
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Table II. Continued.
Venous (27 original questions)
V1. Determine whether prophylactic IVC ﬁlter use reduces PE/death compared with other methods of VTE
prophylaxis, duplex surveillance, or both
V2. Compare the outcomes of treated calf DVT with the natural history of untreated calf DVT
V3. Develop best practices for management of chronic venous ulcer
V4. Compare the effectiveness of compression therapy or ablation with natural history in patients with superﬁcial
venous insufﬁciency
V5. Evaluate chronic cerebrospinous venous insufﬁciency as a cause of multiple sclerosis
Medical management of vascular disease/risk factor modiﬁcation (7 original questions)
M1. Identify and eliminate barriers to vascular surgeons working collaboratively with PCP and cardiologists to
modify atherosclerotic risk factors
M2. Compare preoperative pathways for cardiac risk stratiﬁcation in patients undergoing major vascular procedures
M3. Compare the effectiveness of various medical regimens (antiplatelet, anticoagulation, lipid-lowering agents, etc)
in maintaining or enhancing patency of grafts and other interventions
M4. Deﬁne the most signiﬁcant risk factors for PVD and the role of intervention in reducing PAD
M5. Deﬁne the role of medical optimization before open or endovascular peripheral intervention
M6. Develop and compare effectiveness of clinical strategies to reduce cardiovascular and other perioperative
complications (eg, wound) after open vascular surgery
AAA, Abdominal aortic aneurysm; AV, arteriovenous; CABG, coronary artery bypass graft; CAS, carotid artery stenting; CEA, carotid endarterectomy; CLI,
critical limb ischemia; CTA, computed tomographic angiography; DVT, deep vein thrombosis; EVAR, endovascular aneurysm repair; FMD, ﬁbromuscular
dysplasia; IVC, inferior vena cava; PAD, peripheral artery disease; PCP, primary care physician; PE, pulmonary embolism; PVD, peripheral vascular disease; US,
ultrasound; VTE, venous thromboembolism.
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In addition, based on feedback received from the partici-
pants during this phase of the meeting, several questions
were grouped together, collapsing these 19 questions
into 14, which were then formatted into the ﬁnal scoring
tool (Table IV).
Final ranking. These 14 clinical research priorities
were presented to the entire group (n ¼ 36) in a plenary
session. Each question was presented and discussed. The
outcome of the Improved Nominal Group Technique
of prioritization is presented in Table V. Notably, this
plenary process did not merely ratify the results of the small
group scoring exercise. The ﬁnal group discussion
produced a reordering of priority compared with the
outcome of the small group activity (compare Table III
with Table V).
Postmeeting survey. The postmeeting survey gener-
ated 25 responses from the 38 attendees (66% response
rate). All respondents felt that deﬁning clinical research prior-
ities was an important objective for the SVS, and all felt that
the meeting was worth the time they invested in it. Twenty-
four of the respondents considered the process to be a legiti-
mate mechanism to identify and establish the Society’s
research priorities. The results of the postmeeting survey
can be viewed at http://www.vascularweb.org/research/
clinicalresearch/Pages/Clinical-Research-Priorities-.aspx.
DISCUSSION
The SVS Research Council used a process that started
by identifying a broad representation of clinical research
questions that were important to its membership througha survey followed by reﬁnement and prioritization by
a representative panel of SVS leaders and experts in the
ﬁeld.
The research priorities that emerged from this process
represent a combination of CER questions (#1-3, 5-6, and
9; Table V) where better evidence is needed to make the
best decision possible for an individual patient given several
currently available treatment options. Some of the research
priorities also represent areas where clinical research is
needed to develop better or new therapeutic options for
certain vascular problems (#4, 7, and 8; Table V).
The current set of priorities is notmeant to be permanent
but rather a starting point most likely to achieve the greatest
immediate impact on current clinical practice. If successful,
the process will need to be repeated to update priorities as
gaps in knowledge are ﬁlled, perhaps in as soon as 5 years.
In addition, new knowledge will raise new questions, and
changing population demographics, economic consider-
ations, and health care system dynamics will continuously
inﬂuence research priorities in vascular disease.
Three clinical issues stood out as the highest priority
items for future clinical investigation in the near term.
The fourth-ranking item received less than half the votes
of priority #3 (Table V).
The highest ranking clinical research priority, manage-
ment of asymptomatic carotid disease, is an example of
how best practices evolve and must be revisited as medical
knowledge advances. For many years after the publica-
tion of the Asymptomatic Carotid Atherosclerosis Study,
carotid endarterectomy was the primary means to measur-
ably reduce stroke risk in asymptomatic patients with
Table III. Small group scoring exercise outcome
No. Question Score SD
C5 Deﬁne clinical and anatomic characteristics in asymptomatic carotid stenosis patients that place them at high risk
for stroke
35.72 17.84
C3 Compare effectiveness of invasive intervention (CEA or CAS) with medical therapy for asymptomatic carotid stenosis 31.37 8.81
A8 Identify and evaluate medical therapy to prevent AAA growth 31.31 7.25
P7 Compare effectiveness of medical vs invasive therapy (open or endovascular) for claudication 30.59 7.14
A3 Evaluate US vs CTA surveillance post-EVAR 29.78 6.90
D3 Compare the effectiveness of secondary interventions to preserve existing dialysis access ﬁstulas and grafts 28.77 5.27
P1 Compare effectiveness of initial open vs endovascular infrainguinal revascularization for CLI 28.73 6.02
V3 Develop best practices for management of chronic venous ulcer 28.43 6.54
M6 Develop and compare effectiveness of clinical strategies to reduce cardiovascular and other perioperative
complications (eg, wound) after open vascular surgery
28.24 8.44
D5 Determine the effectiveness of strategies to enhance AV ﬁstula maturation 27.19 5.78
P10 Develop algorithms for cost-effective use of lower extremity revascularization in claudication 26.89 8.99
P6 Develop algorithms for cost-effective use of lower extremity revascularization in CLI 26.84 6.76
D1 Develop a comprehensive cost-effective algorithm for hemodialysis access 24.90 4.61
M3 Compare the effectiveness of various medical regimens (antiplatelet, anticoagulation, lipid-lowering agents, etc) in
maintaining or enhancing patency of grafts and other interventions
24.77 8.02
P3 Deﬁne and evaluate novel strategies for management of unreconstructible CLI including cell- and gene-based therapy 24.76 8.44
M5 Deﬁne the role of medical optimization prior to open or endovascular peripheral intervention 24.07 7.50
V5 Evaluate chronic cerebrospinous venous insufﬁciency as a cause of multiple sclerosis 23.89 8.78
V2 Compare the outcomes of treated calf DVT with the natural history of untreated calf DVT 23.80 10.26
V1 Determine whether prophylactic IVC ﬁlter use reduces PE/death compared with other methods of VTE prophylaxis,
duplex surveillance, or both
23.49 10.17
C6 Deﬁne cost-effective algorithms for imaging carotid disease 23.16 7.14
P13 Evaluate effectiveness of duplex scanning as a surveillance tool to identify and treat asymptomatic recurrence after
endovascular intervention
22.48 8.32
P16 Develop validated quality-of-life measures for patients with vascular disease 21.95 10.70
P15 Compare open vs endovascular management of popliteal aneurysms 21.83 5.77
P9 Compare effectiveness of initial open vs endovascular infrainguinal revascularization for claudication 21.22 10.41
D4 Deﬁne the optimal approach for dialysis access in patients with central venous stenosis 19.27 6.98
P4 Deﬁne the role of primary amputation in CLI 19.22 7.33
P5 Identify the factors predicting successful prosthetic rehabilitation after lower extremity amputation 19.05 7.46
M4 Deﬁne the most signiﬁcant risk factors for PVD and the role of intervention in reducing PAD 18.50 9.87
P12 Deﬁne best medical antiplatelet therapy postintervention for PAD 18.43 8.60
M2 Compare preoperative pathways for cardiac risk stratiﬁcation in patients undergoing major vascular procedures 18.13 8.04
A9 Establish guidelines for AAA screening and deﬁne the “high-risk” small AAAs (<5.5 cm) 17.97 8.53
D2 Deﬁne the optimal form of dialysis access for patients with unsuitable or failed forearm ﬁstulas 17.40 9.89
M1 Identify and eliminate barriers to vascular surgeons working collaboratively with PCP and cardiologists to modify
atherosclerotic risk factors
16.83 9.67
A7 Compare effectiveness of open vs endovascular repair of chronic type B aortic dissections 16.19 7.49
R1 Compare effectiveness of medical therapy vs stenting of severe renal artery disease stratiﬁed by presence of
hypertension and renal insufﬁciency
15.97 8.94
D6 Compare the overall effectiveness of single-stage vs two-stage basilic vein transposition for hemodialysis access 15.35 6.15
C7 Compare observational vs interventional treatment for postintervention carotid restenosis 14.69 7.82
C1 Compare effectiveness of CEA vs CAS for asymptomatic stenosis 14.60 8.88
A5 Determine the natural history of AAAs measuring 5.0-5.5 cm in diameter 14.24 10.86
A2 Compare effectiveness of open vs endovascular repair of thoracoabdominal aneurysms (assume stratiﬁcation by extent) 13.47 7.03
R2 Compare effectiveness of open vs endovascular mesenteric revascularization 12.97 6.91
C8 Deﬁne the role of simultaneous carotid-CABG revascularization 12.91 5.89
C2 Compare effectiveness of CEA vs CAS for symptomatic stenosis 11.63 7.63
V4 Compare the effectiveness of compression therapy or ablation with natural history in patients with superﬁcial venous
insufﬁciency
11.56 5.96
A6 Compare effectiveness of open vs endovascular repair of acute type B aortic dissections 11.44 9.77
A1 Compare effectiveness of open vs endovascular repair of ascending and arch aortic aneurysms 11.38 6.35
P11 Compare duplex vs arteriography as completion study after surgical lower extremity bypass 10.86 5.11
A4 Compare treatment vs observation in AAAs measuring 5.5-6.0 cm in diameter 10.54 8.18
P2 Compare effectiveness of staged vs simultaneous amputation in patients undergoing lower extremity
revascularization with toe or forefoot gangrene
10.30 5.41
C9 Deﬁne the optimal management of patients with low-frequency carotid artery-related pathologies
(eg, hyperperfusion syndrome, dissections, FMD)
8.72 4.33
C4 Compare effectiveness of invasive intervention (CEA or CAS) with medical therapy for symptomatic carotid stenosis 8.53 5.80
P8 Deﬁne the role of infrapopliteal revascularization in diabetics before clinical CLI develops 7.97 6.80
P14 Evaluate methods of diagnosing and treating lower extremity entrapment syndromes 7.37 3.93
AAA, Abdominal aortic aneurysm; AV, arteriovenous; CABG, coronary artery bypass graft; CAS, carotid artery stenting; CEA, carotid endarterectomy; CLI,
critical limb ischemia; CTA, computed tomographic angiography; DVT, deep vein thrombosis; EVAR, endovascular aneurysm repair; FMD, ﬁbromuscular
dysplasia; IVC, inferior vena cava; PAD, peripheral artery disease; PCP, primary care physician; PE, pulmonary embolism; PVD, peripheral vascular disease;
SD, standard deviation; US, ultrasound; VTE, venous thromboembolism.
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Table IV. Final scoring tool
SVS clinical research priorities
Instructions: You have $20 to spend. Using the grid below, spend your entire $20 on the clinical research question(s)
you consider the top priority. Spend in $1 increments only
Question Dollars
Deﬁne optimal management of asymptomatic carotid stenosis (C3 & C5)
Identify and evaluate medical therapy to prevent AAA growth (A8)
Compare effectiveness of medical vs invasive therapy (open or endovascular) for claudication (P7 & P10)
Evaluate US vs CTA surveillance post-EVAR (A3)
Compare effectiveness of secondary interventions to preserve existing dialysis access ﬁstulas and grafts (D1 & D3)
Compare effectiveness of initial open vs endovascular infrainguinal revascularization for CLI (P1 & P6)
Develop best practices for management of chronic venous ulcer (V3)
Develop and compare effectiveness of clinical strategies to reduce cardiovascular and other perioperative
complications (eg wound) after open vascular surgery (M6)
Determine the effectiveness of strategies to enhance AV ﬁstula maturation (D1 & D5)
Deﬁne optimal adjunctive medical therapy to enhance the success of lower extremity intervention (M3 & M5)
Deﬁne and evaluate novel strategies for management of unreconstructible CLI including cell- and gene-based
therapy (P3)
Evaluate chronic cerebrospinous venous insufﬁciency as a cause of multiple sclerosis (V5)
Compare the outcomes of treated calf DVT with the natural history of untreated calf DVT (V2)
Determine whether prophylactic IVC ﬁlter use reduces PE/death compared with other methods of VTE
prophylaxis, duplex surveillance, or both (V1)
Total ¼ $20
AAA, Abdominal aortic aneurysm; AV, arteriovenous; CLI, critical limb ischemia; CTA, computed tomographic angiography; DVT, deep vein thrombosis;
EVAR, endovascular aneurysm repair; IVC, inferior vena cava; PE, pulmonary embolism; US, ultrasound; VTE, venous thromboembolism.
Table V. Final group scoring
SVS clinical research priorities (in order of priority 1-9)
Rank Score($) Clinical research question
1 178 Deﬁne optimal management of asymptomatic carotid stenosis
2 168 Compare effectiveness of medical vs invasive therapy (open or endovascular) for claudication
3 129 Compare effectiveness of initial open vs endovascular infrainguinal revascularization for critical limb ischemia
4 62 Develop and compare effectiveness of clinical strategies to reduce cardiovascular and other perioperative
complications (eg, wound) after vascular intervention
5 61 Deﬁne the effectiveness of strategies to enhance arteriovenous ﬁstula maturation and durability
6 47 Develop best practices for management of chronic venous ulcer
7 36 Deﬁne optimal adjunctive medical therapy to enhance the success of lower extremity intervention
8 32 Identify and evaluate medical therapy to prevent abdominal aortic aneurysm growth
9 7 Evaluate ultrasound vs computed tomographic angiography surveillance postendovascular aneurysm repair
Other questions listed in Table IV received no votes during ﬁnal scoring exercise.
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tomatic Carotid Atherosclerosis Study, and with the publi-
cation of the Carotid Revascularization Endarterectomy
Versus Stenting Trial study, carotid stenting is now consid-
ered by many to be an alternative to endarterectomy.6 In
addition, the natural history of asymptomatic carotid
stenosis may have been altered and improved with modern
medical management (eg, statins). Therefore, many
vascular specialists now regard operative or catheter-based
treatment of asymptomatic patients with high-grade
carotid stenosis as an area of equipoise. Others question
the value of intervention altogether given that better
medical therapy may have reduced the already small abso-
lute stroke risk reduction observed in older trials such as
the Asymptomatic Carotid Atherosclerosis Study.The optimal management of vasculogenic claudication
has not been deﬁned. The recently published Claudication:
Exercise Versus Endoluminal Revascularization trial sug-
gested that noninterventional therapy was as effective
as stenting if the measured outcome is treadmill walking
distance but studied a highly select population with
aortoiliac disease and did not include an open surgical
arm.7 Another recently published trial of supervised exer-
cise compared with percutaneous angioplasty in claudicants
with femoropopliteal disease also failed to show the conclu-
sive evidence for superiority of interventional treatment.8
Again, this trial did not include a surgical arm. These results
are sobering for vascular specialists who have anecdotally
witnessed patients experience dramatic relief of vasculo-
genic claudication with mechanical intervention. At a
JOURNAL OF VASCULAR SURGERY
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needed to better identify those patients most likely to
beneﬁt from invasive treatment. The optimal role of
surgical intervention in the management of vasculogenic
claudication relative to other options remains unaddressed.
Which patients with critical limb ischemia should be
initially treated with endovascular or open surgical revascu-
larization is also highly controversial, and little widely appli-
cable information in this area has emerged since
publication of the Bypass vs Angioplasty in Severe Is-
chaemia of the Leg trial.9-11
As a professional society devoted to the comprehensive
management of vascular disease, the SVS offers these
heavily vetted research priorities to the vascular and broader
medical community for consideration. The SVS Research
Council is developing programs for the coming years based
on this foundation to accelerate generation of new knowl-
edge in these pivotal areas. Funding agencies such as the
National Institutes of Health, Veterans Administration,
and American Heart Association will be invited to consider
the priorities identiﬁed during this initiative and will be
encouraged to develop targeted research opportunities
addressing these critical priorities, where allocation of
resources is likely to generate the greatest return on invest-
ment and patient care beneﬁt.
The authors recognize the helpful criticism and review
of the manuscript by Patrick Geraghty, Peter Henke,
Thomas Huber, William Jordan, Lois Killewich, Glenn
LaMuraglia, Gregory Moneta, Peter Nelson, John Ricotta,
Caron Rockman, Russell Samson, Marc Schermerhorn,
Omaida Velazquez, and Thomas Wakeﬁeld. Sarah Murphy
provided valuable administrative support throughout the
process of establishing SVS research priorities and subse-
quent publication.
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